The Quantum Newsroom
Evidence, in the open.
The Cost of Guessing: what a wrong site really costs
Guessing is free. Being wrong is not. The activation fee, the wait, the rescue site, the amendment, the delay — the itemized bill for choosing sites on intuition instead of evidence, with the industry numbers behind each line and the sources to back them.
They guess. We count.
Most site-selection tools infer where patients probably are from a partial sample. We count the actual patients, across every institution — and why that difference decides a rare-disease trial.
Read →A few hundred patients. The whole country.
An expert sees their clinic. Nobody sees the whole country. Why rare-disease feasibility asks two questions in order, and why the conventional shortlist of marquee centers answers the wrong one.
Read →How to win a bid defense on real patient data
What a bid defense is, the one question it turns on, the six things that turn the meeting from a pitch into a proof, and the deliverable you walk in with. Presented as the deck itself.
Read the guide →Introducing the AI Founding Partner Program
A feasibility engine built inside your own cloud, trained on your data, seen by no one. A small number of Founding Partner slots for CROs who run feasibility at scale.
Coming soonMedia enquiries: marketing@quantumresearch.cloud
Nothing in this section yet — more is on the way.
They guess. We count.
Let’s talk about your study.
We will show you the qualifying patients and the investigators who will enroll them — the evidence you walk into the bid defense with.